EEG-based biomarker might help predict psychotic disorders; QuanDx raises money to advance molecular Dx cancer test platform;

> Researchers are studying an EEG-based biomarker that may help predict psychotic disorders in high-risk individuals. Item

> Chembio Diagnostics ($CEMI) has named a veteran executive from companies now part of Siemens' ($SI) and Roche's ($RHHBY) diagnostic divisions as its new CEO. Story

> PerkinElmer ($PKI) will help expand access to in vitro fertilization genetic screening tests made by Good Start Genetics in a new collaboration deal. Release

> California's QuanDx raised a $1.25 million Series B round to help advance development of its molecular diagnostic platform for cancer, plus genetic and infectious diseases. Release

> Madison, WI-based Stemina Biomarker Discovery is raising $10 million to advance biomarker tests for autism. Story

> AdvanDx is seeking 510(k) clearance for a new test for the rapid detection of MRSA from S. aureus-positive blood cultures. Release

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.